Azitra

Azitra holds $3.8M cash against $3.0M Q3 loss as ATR-04 advances

Image
Azitra holds $3.8M cash against $3.0M Q3 loss as ATR-04 advances

BRANFORD -- November 12, 2026 -- Azitra (NYSE American: AZTR) ended the quarter on September 30, 2026 with $3.8 million in cash and cash equivalents, about 1.3 times its $3.0 million net loss for the quarter. The company says investors in its March 2026 private placement can put in a further $5.25 million to $10.5 million once it reports first-in-human results for its ATR-COSF cosmetic ingredient, which it expects by year-end 2026.

Azitra's quarterly net loss widens 7% while administrative costs stay flat

Net loss was $3.0 million, up from $2.8 million in the third quarter of 2025, an increase of about 7% by FairsOnline's calculation. Research and development expenses rose to $1.3 million from $1.2 million, about 8%. General and administrative expenses were $1.6 million in both periods. Together, R&D and G&A come to $2.9 million, most of the quarter's loss.